Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Medical Developments International (ASX:MVP), maker of the Penthrox pain relief inhaler, has delivered improved results, according to Saville Capital. In July 2026, Saville reported a very solid fourth quarter and FY26 result relative to initial guidance, with revenue of $42.6 million, up 9%, underpinned by its pain management business. Saville noted earlier quarters showed revenue growth of up to 18%, driven by strong Penthrox volume growth in Australia and overseas. Medical Developments operates in the Healthcare sector within the Pharmaceuticals industry, and Thesis Tracker has captured 4 comments from 1 fund manager, Saville Capital. Founded in 1971 and headquartered in Scoresby, Melbourne, Medical Developments International manufactures and distributes Penthrox, an inhaled analgesic for emergency pain relief used by ambulances, hospitals and sports clubs in Australia, Europe and other markets, as well as respiratory devices such as spacers, and has restructured to focus on profitable growth.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Saville Capital have invested in Medical Developments International Ltd (ASX:MVP).
Saville highlights solid results ahead of initial guidance, strong Penthrox volume growth domestically and internationally and improving revenue.
The available commentary does not set out specific risks, though growth depends on regulatory approvals and adoption of Penthrox in new markets such as the US.
Medical Developments International Ltd., founded in 1971 and headquartered in Scoresby, Australia, manufactures and distributes pharmaceutical, medical, and veterinary products. The company operates through three core segments: Pharmaceuticals, focusing on the sale of Penthrox; Medical Equipment, providing medical devices; and Veterinary Equipment, supplying veterinary products. Its operations span markets in Australia, Europe, and Asia. MDI provides essential drugs and equipment to healthcare and veterinary sectors, maintaining a focused approach across its established global business segments.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.